Strategies for Switching from GLP-1 to Insulin Before Elective Surgery
Elective surgical procedures often require careful coordination of a patient’s diabetes regimen to ensure optimal glycemic control and reduce the risk of peri‑operative complications. For individuals currently on glucagon‑like peptide‑1 (GLP‑1) receptor agonists—such as Ozempic, Wegovy, Mounjaro, or Zepbound—the transition to insulin coverage is a common practice. This article outlines a practical, step‑by‑step protocol that clinicians and patients can follow when planning a surgical transition, emphasizing safety, communication, and evidence‑based care.
Why Transition from GLP-1 to Insulin?
GLP‑1 receptor agonists are prized for their ability to lower blood glucose, promote weight loss, and provide cardiovascular benefits. However, several factors make insulin the preferred agent in the peri‑operative setting:
- Predictable pharmacokinetics: Insulin’s onset and duration can be precisely titrated, which is essential when patients are fasting.
- Reduced gastrointestinal side effects: GLP‑1 agents often cause nausea or delayed gastric emptying, complicating pre‑operative fasting guidelines.
- Rapid reversal: If hypoglycemia occurs intra‑operatively, insulin can be quickly stopped, whereas GLP‑1 effects linger longer.
These considerations help maintain stable blood glucose levels, minimize infection risk, and support wound healing.
Pre‑Operative Assessment
Before any medication change, a comprehensive evaluation is essential. The following steps should be completed at least two weeks prior to the scheduled surgery:
- Review the patient’s diabetes history: Duration of disease, prior hypoglycemia episodes, and current HbA1c values.
- Identify the specific GLP‑1 agent: Dosing schedule, last administration date, and any recent dose adjustments.
- Assess renal and hepatic function: Both influence insulin clearance and dosing requirements.
- Coordinate with the surgical team: Confirm fasting instructions, anticipated operative time, and postoperative pain management plan.
- Develop a personalized insulin regimen: Determine basal and prandial insulin needs based on the patient’s typical carbohydrate intake and activity level.
Documenting these details in the medical record ensures continuity of care across the pre‑, intra‑, and post‑operative phases.
Stepwise Transition Protocol
The following protocol outlines a typical timeline for moving from a GLP‑1 receptor agonist to insulin. Adjustments may be necessary based on individual patient factors.
1. Discontinue GLP‑1 48–72 Hours Before Surgery
Most GLP‑1 agents have a half‑life ranging from 1 to 5 days. Stopping the medication 48–72 hours prior allows the drug to clear sufficiently, reducing the risk of lingering gastrointestinal effects while still preserving some glycemic benefit.
2. Initiate Basal Insulin Coverage
Begin a long‑acting insulin (e.g., glargine or detemir) at a dose roughly equivalent to the patient’s total daily insulin requirement, calculated as 0.2–0.3 units/kg. For patients previously well‑controlled on GLP‑1 alone, a conservative starting dose of 0.1–0.15 units/kg is advisable to avoid hypoglycemia.
3. Adjust Dosing Based on Fasting Blood Glucose
During the 24‑hour pre‑operative fasting period, monitor capillary glucose every 4–6 hours. If values trend above 180 mg/dL (10 mmol/L), increase the basal insulin by 10–20 %. Conversely, if glucose falls below 80 mg/dL (4.4 mmol/L), reduce the dose accordingly.
4. Introduce Prandial Insulin on the Day of Surgery
If the patient will receive any carbohydrate‑containing fluids (e.g., clear broth) before anesthesia, administer a rapid‑acting insulin (lispro, aspart, or glulisine) at 0.05–0.1 units/kg per carbohydrate load. This step is optional for strictly NPO (nil per os) cases.
5. Intra‑Operative Management
During anesthesia, maintain glucose between 140–180 mg/dL (7.8–10 mmol/L) using an insulin infusion if necessary. Frequent point‑of‑care testing (every 30–60 minutes) helps guide adjustments.
6. Post‑Operative Transition Back to Home Regimen
Once oral intake resumes, reassess the need for basal insulin versus a return to GLP‑1 therapy. If the patient tolerates the GLP‑1 agent without nausea and demonstrates stable glucose, the insulin can be tapered over 2–3 days while re‑introducing the GLP‑1 dose.
Monitoring Glycemic Control
Effective monitoring is the cornerstone of a safe surgical transition. Key practices include:
- Frequent glucose checks: Aim for at least four daily readings during the peri‑operative window.
- Use of continuous glucose monitoring (CGM): When available, CGM provides real‑time trends and alerts for hypo‑ or hyperglycemia.
- Documentation of insulin doses: Record each administration, including timing relative to meals and procedures.
- Prompt communication: Any unexpected glucose excursions should be reported immediately to the anesthesia team.
These measures help clinicians intervene quickly, reducing the likelihood of complications such as surgical site infections or delayed wound healing.
Patient Education and Support
Empowering patients with knowledge enhances adherence to the transition plan. Education should cover:
- The reason for stopping GLP‑1 therapy before surgery.
- How to recognize symptoms of hypoglycemia (shakiness, sweating, confusion) and appropriate corrective actions.
- Instructions for using insulin pens or syringes, including proper storage and disposal.
- The importance of keeping a log of blood glucose readings and insulin doses.
- When to seek medical help—particularly if glucose remains consistently above 250 mg/dL (13.9 mmol/L) or below 70 mg/dL (3.9 mmol/L).
Providing written handouts and reinforcing instructions during pre‑operative visits can improve confidence and outcomes.
Getting Started with GLP-1
For patients who have not yet initiated GLP‑1 therapy, understanding eligibility and selecting the appropriate formulation are essential first steps. A licensed online provider can streamline the screening process, ensuring that candidates meet clinical criteria and receive personalized dosing guidance. To determine if you qualify for GLP‑1 treatment, check your eligibility here.
Frequently Asked Questions
Can I resume my GLP‑1 medication the day after surgery?
In most cases, patients can restart GLP‑1 therapy once they tolerate solid foods and have stable glucose levels for at least 24 hours. However, the timing should be individualized based on the surgical procedure and any postoperative complications.
What if my blood glucose remains high despite insulin adjustments?
Persistent hyperglycemia may indicate the need for a higher basal insulin dose, addition of a rapid‑acting insulin bolus, or temporary use of an insulin infusion. Always discuss persistent elevations with the surgical and endocrinology teams.
Is it safe to use a continuous glucose monitor (CGM) during surgery?
CGM devices can be used in the peri‑operative setting, but they should not replace point‑of‑care glucose testing for intra‑operative decisions. Verify that the hospital’s policies allow CGM use and have a backup fingerstick method ready.
Do all GLGL‑1 agents require the same discontinuation interval?
While the general recommendation is to stop GLP‑1 agents 48–72 hours before surgery, the exact timing may vary. For example, Ozempic and Wegovy have longer half‑lives than shorter‑acting formulations, so a longer washout period may be prudent. Consult the prescribing information for each specific product.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any changes to your diabetes treatment plan, especially in the context of surgery.